A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Inclusion Criteria:

• Clinical diagnosis of PN ≥ 3 months before screening.

• Pruriginous lesions (defined as papules, nodules, plaques, umbilicated lesions, andlinear lesions) on ≥ 2 different body areas (such as right and left leg) atscreening and baseline.

• Total estimated treatment BSA ≥ 25% (excluding the scalp) at screening and baseline.

• IGA-CPG-S score of ≥ 2 at screening and baseline.

• Baseline PN-related WI-NRS score ≥ 7. Baseline WI-NRS score is defined as the 7-dayaverage of WI-NRS scores before Day 1 (data from a minimum of 4 out of 7 days priorto Day 1 is needed).

Exclusion Criteria:

• Chronic or acute pruritus due to a condition other than PN.

• Active AD lesions (signs and symptoms other than dry skin) within 6 months ofscreening and baseline.

• Acute or chronic active HBV or HCV infection.

• Any underlying condition known to be associated with the clinical presentation of PNthat is not under control (stable) prior to the baseline visit.

• Any serious illness or medical, physical, or psychiatric condition(s) that, in theinvestigator's opinion, would interfere with full participation in the study,including administration of study cream and attending required study visits; pose asignificant risk to the participant; or interfere with interpretation of study data.

Other protocol-defined Inclusion/Exclusion Criteria may apply.